Skip to search formSkip to main contentSkip to account menu

AM 803

Known as: AM-803, GSK2190915 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
2014
2014
Exercise-induced bronchoconstriction (EIB) describes the condition whereby exercise causes airflow obstruction that lasts for up… 
2014
2014
Pharmacokinetic variability in drug exposure is a concern for all compounds in development including those for the treatment of… 
Review
2014
Review
2014
As illustrated within the pages of the current issue of the Proceedings, the specialty of allergy–immunology encompasses a… 
2013
2013
GSK2190915, a potent 5‐lipoxygenase‐activating protein inhibitor, prevents the synthesis of leukotrienes and 5‐oxo‐6,8,11,14… 
2013
2013
BackgroundGSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma… 
2013
2013
AIM To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor… 
2013
2013
Abstract Objective: To investigate the clinical benefits of ‘add-on’ therapy with GSK2190915 in combination with the inhaled… 
2013
2013
Background GSK2190915, a 5-lipoxygenase activating protein inhibitor, inhibits the production of cysteinyl leukotrienes and…